Illumina, Inc. (0J8Z.L)
USD 137.9
(-3.76%)
USD 137.9
(-3.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.21 Billion USD | -17.3% |
| 2022 | 1.46 Billion USD | 18.67% |
| 2021 | 1.23 Billion USD | 2648.89% |
| 2020 | 45 Million USD | 121.84% |
| 2019 | -206 Million USD | -124.15% |
| 2018 | 853 Million USD | 668.47% |
| 2017 | 111 Million USD | -79.34% |
| 2016 | 537.27 Million USD | 66.95% |
| 2015 | 321.8 Million USD | -50.86% |
| 2014 | 654.88 Million USD | 317.24% |
| 2013 | 156.95 Million USD | -61.57% |
| 2012 | 408.39 Million USD | -19.03% |
| 2011 | 504.39 Million USD | 704.94% |
| 2010 | 62.66 Million USD | -56.95% |
| 2009 | 145.56 Million USD | 99.48% |
| 2008 | 72.97 Million USD | -67.58% |
| 2007 | 225.07 Million USD | 687.31% |
| 2006 | -38.32 Million USD | 24.34% |
| 2005 | -50.65 Million USD | 7.55% |
| 2004 | -54.78 Million USD | -516.55% |
| 2003 | 13.15 Million USD | -45.78% |
| 2002 | 24.26 Million USD | 840.09% |
| 2001 | -3.27 Million USD | 97.15% |
| 2000 | -114.95 Million USD | -443.19% |
| 1999 | -21.16 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.16 Billion USD | -3.79% |
| 2024 Q3 | 1.73 Billion USD | -9.8% |
| 2024 Q2 | 2 Billion USD | 71.32% |
| 2023 Q4 | 1.21 Billion USD | -3.65% |
| 2023 Q3 | 1.26 Billion USD | -10.7% |
| 2023 FY | 1.21 Billion USD | -17.3% |
| 2023 Q1 | 1.48 Billion USD | 1.43% |
| 2023 Q2 | 1.41 Billion USD | -5.24% |
| 2022 Q3 | 1.48 Billion USD | 14.45% |
| 2022 Q4 | 1.46 Billion USD | -1.41% |
| 2022 FY | 1.46 Billion USD | 18.67% |
| 2022 Q1 | 1.26 Billion USD | 2.18% |
| 2022 Q2 | 1.3 Billion USD | 2.93% |
| 2021 Q2 | -1.81 Billion USD | -12.68% |
| 2021 FY | 1.23 Billion USD | 2648.89% |
| 2021 Q1 | -1.6 Billion USD | -3675.56% |
| 2021 Q4 | 1.23 Billion USD | -11.07% |
| 2021 Q3 | 1.39 Billion USD | 176.72% |
| 2020 FY | 45 Million USD | 121.84% |
| 2020 Q1 | -144 Million USD | 30.1% |
| 2020 Q2 | 73 Million USD | 150.69% |
| 2020 Q4 | 45 Million USD | -50.0% |
| 2020 Q3 | 90 Million USD | 23.29% |
| 2019 Q4 | -206 Million USD | -3042.86% |
| 2019 FY | -206 Million USD | -124.15% |
| 2019 Q3 | 7 Million USD | 105.6% |
| 2019 Q1 | 191 Million USD | -77.61% |
| 2019 Q2 | -125 Million USD | -165.45% |
| 2018 FY | 853 Million USD | 668.47% |
| 2018 Q1 | -209 Million USD | -288.29% |
| 2018 Q2 | 25 Million USD | 111.96% |
| 2018 Q3 | 643 Million USD | 2472.0% |
| 2018 Q4 | 853 Million USD | 32.66% |
| 2017 Q1 | 267 Million USD | -50.3% |
| 2017 Q4 | 111 Million USD | 331.25% |
| 2017 Q3 | -48 Million USD | -160.76% |
| 2017 Q2 | 79 Million USD | -70.41% |
| 2017 FY | 111 Million USD | -79.34% |
| 2016 FY | 537.27 Million USD | 66.95% |
| 2016 Q4 | 537.27 Million USD | 26.23% |
| 2016 Q3 | 425.62 Million USD | 430.58% |
| 2016 Q2 | 80.21 Million USD | -70.04% |
| 2016 Q1 | 267.73 Million USD | -16.8% |
| 2015 Q1 | 767.66 Million USD | 17.22% |
| 2015 FY | 321.8 Million USD | -50.86% |
| 2015 Q2 | 712.21 Million USD | -7.22% |
| 2015 Q4 | 321.8 Million USD | -42.39% |
| 2015 Q3 | 558.57 Million USD | -21.57% |
| 2014 Q3 | 451.06 Million USD | -24.29% |
| 2014 FY | 654.88 Million USD | 317.24% |
| 2014 Q4 | 654.88 Million USD | 45.19% |
| 2014 Q2 | 595.74 Million USD | 80.8% |
| 2014 Q1 | 329.5 Million USD | 109.93% |
| 2013 FY | 156.95 Million USD | -61.57% |
| 2013 Q4 | 156.95 Million USD | -6.39% |
| 2013 Q1 | 417.65 Million USD | 2.27% |
| 2013 Q2 | 68.28 Million USD | -83.65% |
| 2013 Q3 | 167.66 Million USD | 145.52% |
| 2012 FY | 408.39 Million USD | -19.03% |
| 2012 Q1 | 555.77 Million USD | 10.19% |
| 2012 Q3 | 490.38 Million USD | -3.52% |
| 2012 Q4 | 408.39 Million USD | -16.72% |
| 2012 Q2 | 508.25 Million USD | -8.55% |
| 2011 Q3 | 569.02 Million USD | 6.0% |
| 2011 FY | 504.39 Million USD | 704.94% |
| 2011 Q4 | 504.39 Million USD | -11.36% |
| 2011 Q2 | 536.83 Million USD | 52.05% |
| 2011 Q1 | 353.06 Million USD | 463.44% |
| 2010 Q4 | 62.66 Million USD | -34.27% |
| 2010 FY | 62.66 Million USD | -56.95% |
| 2010 Q3 | 95.33 Million USD | 50.1% |
| 2010 Q1 | 82.17 Million USD | -43.55% |
| 2010 Q2 | 63.51 Million USD | -22.71% |
| 2009 Q4 | 145.56 Million USD | 215.22% |
| 2009 FY | 145.56 Million USD | 99.48% |
| 2009 Q1 | -76.35 Million USD | -204.63% |
| 2009 Q2 | -72.39 Million USD | 5.19% |
| 2009 Q3 | 46.18 Million USD | 163.79% |
| 2008 Q1 | 281.39 Million USD | 25.02% |
| 2008 Q3 | 45.36 Million USD | -83.91% |
| 2008 Q4 | 72.97 Million USD | 60.85% |
| 2008 FY | 72.97 Million USD | -67.58% |
| 2008 Q2 | 281.91 Million USD | 0.19% |
| 2007 Q3 | 335.91 Million USD | 5.33% |
| 2007 Q1 | 276.54 Million USD | 821.61% |
| 2007 FY | 225.07 Million USD | 687.31% |
| 2007 Q2 | 318.92 Million USD | 15.33% |
| 2007 Q4 | 225.07 Million USD | -33.0% |
| 2006 FY | -38.32 Million USD | 24.34% |
| 2006 Q2 | -152.13 Million USD | -211.11% |
| 2006 Q1 | -48.9 Million USD | 3.45% |
| 2006 Q3 | -44.07 Million USD | 71.03% |
| 2006 Q4 | -38.32 Million USD | 13.04% |
| 2005 Q2 | -54.56 Million USD | -3.05% |
| 2005 FY | -50.65 Million USD | 7.55% |
| 2005 Q4 | -50.65 Million USD | -0.95% |
| 2005 Q3 | -50.17 Million USD | 8.05% |
| 2005 Q1 | -52.95 Million USD | 3.35% |
| 2004 FY | -54.78 Million USD | -516.55% |
| 2004 Q3 | -54.32 Million USD | -87.77% |
| 2004 Q2 | -28.93 Million USD | -273.29% |
| 2004 Q4 | -54.78 Million USD | -0.86% |
| 2004 Q1 | 16.69 Million USD | 26.93% |
| 2003 Q3 | 15.8 Million USD | -18.94% |
| 2003 Q4 | 13.15 Million USD | -16.75% |
| 2003 FY | 13.15 Million USD | -45.78% |
| 2003 Q1 | 21.08 Million USD | -13.08% |
| 2003 Q2 | 19.49 Million USD | -7.56% |
| 2002 FY | 24.26 Million USD | 840.09% |
| 2002 Q1 | 15.82 Million USD | 582.82% |
| 2002 Q2 | 25.47 Million USD | 60.93% |
| 2002 Q3 | 24.92 Million USD | -2.14% |
| 2002 Q4 | 24.26 Million USD | -2.67% |
| 2001 Q1 | -112.51 Million USD | 2.12% |
| 2001 Q2 | -10.4 Million USD | 90.75% |
| 2001 Q4 | -3.27 Million USD | -17.56% |
| 2001 Q3 | -2.78 Million USD | 73.19% |
| 2001 FY | -3.27 Million USD | 97.15% |
| 2000 Q2 | -18.32 Million USD | -21.65% |
| 2000 Q4 | -114.95 Million USD | 4.5% |
| 2000 Q1 | -15.06 Million USD | 0.0% |
| 2000 Q3 | -120.37 Million USD | -556.74% |
| 2000 FY | -114.95 Million USD | -443.19% |
| 1999 FY | -21.16 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 1493.544% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1038.463% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 3720.962% |
| Perrigo Company plc | 3.32 Billion USD | 63.457% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 95.477% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1165.96% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 85.258% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 90.556% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -736.803% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 4579.705% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -16791.61% |
| Waters Corporation | 1.96 Billion USD | 38.075% |
| Biogen Inc. | 6.28 Billion USD | 80.694% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 17198.592% |
| Evolus, Inc. | 63.7 Million USD | -1805.569% |
| Adicet Bio, Inc. | -142 Million USD | 954.881% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 13564.951% |
| bluebird bio, Inc. | 108.57 Million USD | -1018.162% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -164.662% |
| FibroGen, Inc. | 56.76 Million USD | -2038.566% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -6.026% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -17322.313% |
| Homology Medicines, Inc. | 18.43 Million USD | -6484.585% |
| Geron Corporation | 14.76 Million USD | -8124.375% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 23.423% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -512.93% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1277.98% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 2337.541% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1189.747% |
| Zoetis Inc. | 4.76 Billion USD | 74.507% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 12154.414% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 42.134% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -220.53% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 112.694% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 8431.046% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -15.15% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -3707.433% |
| Verastem, Inc. | -37.27 Million USD | 3356.612% |
| Nektar Therapeutics | 210.24 Million USD | -477.435% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 707.544% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 3398.555% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -25.364% |
| OPKO Health, Inc. | 230.68 Million USD | -426.263% |
| Exelixis, Inc. | -73.05 Million USD | 1761.875% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -584.715% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 996.603% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 903.846% |
| uniQure N.V. | -102.95 Million USD | 1279.202% |
| Imunon, Inc. | -4.69 Million USD | 25933.783% |
| Blueprint Medicines Corporation | 702.83 Million USD | -72.729% |
| Insmed Incorporated | 721.62 Million USD | -68.233% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 12.085% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 3988.907% |
| TG Therapeutics, Inc. | 17.86 Million USD | -6696.551% |
| Incyte Corporation | -3.17 Billion USD | 138.235% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -58.527% |